2017-2009 Press Releases
2017
March 13, 2017
Distinguished Cancer Physician-Scientist Dr. Herbert (Bob) Pinedo joins Amunix Scientific Advisory Board
February 15, 2017
Amunix announces broad alliance with Genentech using XTEN® technology
February 13, 2017
Amunix Appoints Fred Hausheer, MD, FACP, as Chief Medical Officer
2016
December 19, 2016
IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
September 29 2016
Phase 3 enrollment initiated in Japan for Versartis’ long-acting growth hormone based on Amunix’ XTEN® technology
September 1, 2016
Long acting growth hormone based on Amunix’ XTEN® technology completes enrollment of Phase 3 trial
August 22, 2016
Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD
March 3, 2016
Harold E. “Barry” Selick, Ph.D. and Walter H. Moos, Ph.D. Join Amunix Board of Directors
2015
November 16, 2015
Amunix Establishes GMP Manufacturing of XTEN® at UN-L BPDF
October 26, 2015
Amunix, Inc. Announces Extension of Evaluation Agreement with Roche (RHHBY)
September 18, 2015
Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Growth-Hormone-XTEN (VRS-317, Somavaratan) in Children.
January 5, 2015
Amunix Announces Exclusive Agreements with Naia to Develop GLP-1 and GLP-2 XTEN® Products
2014
December 17, 2014
Amunix Announces Option Exercise by Eli Lilly and Company for XTEN® Product for People with Diabetes
October 28, 2014
Amunix and PolyPeptide Enter Into Partnership to Produce XTEN® Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics
October 27, 2014
Amunix Signs a Services and Supply Agreement With the University of Nebraska-Lincoln to Produce GMP-Grade XTEN® for Pharmaceutical Therapeutics
June 30, 2014
Amunix Congratulates Versartis on its Positive Phase 2a Results with VRS-317
June 5, 2014
Amunix Presents XTEN® Half-life Extension Technology at Next Generation Protein Therapeutics Summit
May 28, 2014
Amunix to Present Unpublished Data at Next Generation Protein Therapeutics Summit
April 21, 2014
Biogen Idec Signs License Agreement with Amunix for XTENylated Factor VIII
January 7, 2014
Amunix Announces Expansion to Licensing Agreement with Janssen for Its Proprietary XTEN® Technology
2013
August 14, 2013
Amunix Announces Update to Licensing Agreement with Janssen for Its Proprietary XTEN Technology
July 1, 2013
Preclinical Data from Biogen Idec-Amunix Partnership Presented at ISTH Congress
January 21, 2013
Amunix Announces Licensing Agreement for its Proprietary XTEN Technology
2011
April 13, 2011
Amunix Signs Research Collaboration with Biogen Idec for Next Generation Long-Lasting Blood Factor Products
2009
November 15, 2009
XTEN Data from Amunix and Versartis Featured in Nature Biotechnology as a Novel Platform for Increasing Serum Half-life of Protein Therapeutics